// App-Quantinova.ai

2075 : Differential tissue clearance results in improved therapeutic index for irinotecan liposome injection (ONIVYDE) when combined with the PARP inhibitor veliparib in preclinical cervical tumors

Researchers

Presenter

  • Alexander Koshkaryev

Principal Investigators

  • Jonathan Fitzgerald

  • Jaeyeon Kim

  • Ashish Kalra

  • Walid Kamoun

  • Sarah Blanchette

  • Lia Luus

  • Stephan Klinz

  • Ozan Alkan

  • Tad Kornaga

  • Susan Bates

  • Yves Pommier

  • Daryl C. Drummond

Medical Centers

  • Merrimack Pharmaceuticals, Cambridge, MA

  • Merrimack, Cambridge, MA

  • Columbia University, New York, NY

  • National Cancer Institute, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Irinotecan

  • Gemcitabine

  • Veliparib

  • ribose

  • Adrucil injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved